EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosisAL amyloidosis14 June 2020
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patientsAccess, Myeloma14 May 2020
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?AL amyloidosis, MPE, Myeloma8 May 2020
MPE webinar on personalised medicines in myeloma and AL amyloidosisAL amyloidosis, MPE, Myeloma28 April 2020
New clinical trial to evaluate the myeloma drug selinexor as potential treatment for patients with COVID-19Myeloma14 April 2020
MPE webinar on Minimal Residual Disease (MRD) in myeloma and related diseasesMPE, Myeloma13 April 2020
